Abbott plans marketing push for glucose monitors beyond diabetes
By Leroy Leo and Puyaan Singh
July 18 (Reuters) -Abbott Laboratories ABT.N will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Fordsaid on Thursday.
The company plans to launch the over-the-counter device, Lingo, this year. It could be a multi-billion-dollar product for Abbott, Ford estimated, adding it was still in its early days.
Lingo and Libre Rio, another of Abbott's devices,received clearance from the U.S. Food and Drug Administration's last month.
Lingo targets consumers who want to better understand their health, while Libre Rio is for adults with type 2 diabetes who do not need insulin.
Abbott is a key player in the marketfor continuous glucose monitors sold under prescription to diabetes patients, along with rivals DexCom DXCM.O and Medtronic MDT.N.
FreeStyle Libre, Abbott's blood sugar monitor, generated $1.6 billion in salesglobally in the second quarter. However,the company said the marketing for a consumer product would greatly differ from that for a medical device.
"I don't think, givenour experience here, that you can just go on TV, blast TV advertising and you'll get this big uptake. You are going to have to do some on-the-ground kind of guerilla marketing," Ford said during an analyst conference call.
Guerilla marketing uses tactics such ason-ground outreach, social media campaigns, among others, and usually involve low budgets.
Ford expects sales growth for Lingo to ramp up over time as the company builds the market.
RBC Capital Markets analyst Shagun Singh does not currently model much in sales of Abbott and Dexcom's OTC products, but believes the market would be significant.
Abbott is "literally just launching it this summer. So there will be a lot to learn for us, but substantial opportunities for both companies," said Singh.
Olympic athletes turn to diabetes tech in pursuit of medals https://www.reuters.com/sports/olympics/olympic-athletes-turn-diabetes-tech-pursuit-medals-2024-06-10/
Reporting by Leroy Leo and Puyaan Singh in Bengaluru; Editing by Shreya Biswas
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
